FFT Wealth Management’s INmune Bio INMB Stock Holding History

FFT Wealth Management’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-25	Closed	–	–	168
2021 Q2	$0	Buy	+25	New	+$337	﹤0.01%	248

Other funds holding INMB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

FFT Wealth Management's INMB Position: Q3 2021 in Review

FFT Wealth Management sold out of INmune Bio (INMB) in Q3 2021, closing a stake of 25 shares.

FFT Wealth Management first reported a position in INMB in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 41 funds tracked by Wall St. Rank hold INMB as of Q3 2021.

FFT Wealth Management reported no remaining INmune Bio position as of Q3 2021 after selling out during the quarter.
FFT Wealth Management sold 25 INmune Bio shares in Q3 2021.
FFT Wealth Management first reported a position in INmune Bio in Q2 2021 and held it in 1 quarter.
FFT Wealth Management's INmune Bio position peaked at $0 in Q2 2021.
41 funds tracked by Wall St. Rank held INmune Bio as of Q3 2021.

Based on FFT Wealth Management's 13F filing for Q3 2021, filed 12 Nov 2021.